Abstract
Introduction: Non-alcoholic fatty liver disease (NAFLD) is currently the most common type of chronic liver disease. Semaglutide is a glucose-lowering drug administered for the treatment of type 2 diabetes mellitus (T2DM) and is clinically effective in the treatment of NAFLD. X-box binding protein 1 (XBP1) is related to the pathogenesis of both NAFLD and T2DM. The aim of the present study was to demonstrate whether the underlying mechanism of semaglutide treatment for NAFLD is via downregulation of the inositol-requiring transmembrane kinase/endonuclease-1α (IRE1α)-XBP1-CCAAT/enhancer binding protein α (C/EBPα) signaling pathway in macrophages. Methods: In the present study, NAFLD cell modeling was induced by oleic acid (0.4 mm) and palmitic acid (0.2 mm). Hepatocytes (AML12) and macrophages (RAW264.7) were co-cultured in 6-well Transwell plates. Semaglutide (60 or 140 nm) was administrated for 24 h, while pioglitazone (2 μm) and toyocamycin (200 nm) were used as a positive control drug and a XBP1 inhibitor, respectively. Autophagy and apoptosis of AML12 cells were detected by transmission electron microscopy and Western blotting (WB). Hepatocyte steatosis was evaluated by adopting total intracellular triglyceride determination, analysis of the relative expression of proteins and genes associated with lipid metabolism and hepatocyte Oil red O staining. Detection of inflammation factors was conducted by ELISA and WB. To explore the underlying mechanism of NAFLD treatment with semaglutide, the relative expression of related proteins and genes were tested. Results: Our study demonstrated that semaglutide treatment improved autophagy and inhibited apoptosis of hepatocytes, while notably ameliorating steatosis of hepatocytes. In addition, inflammation was attenuated in the NAFLD cell co-culture model after semaglutide administration. Semaglutide also significantly reduced the protein and gene expression levels of the IRE1α-XBP1-C/EBPα signaling pathway in macrophages. Conclusion: Semaglutide partially ameliorated NAFLD by downregulating the IRE1α-XBP1-C/EBPα signaling pathway in macrophages. These findings may provide a potential theoretical basis for semaglutide therapy for NAFLD.
Journal Section:
Research Article
References
1.
Cusi
K
, Isaacs
S
, Barb
D
, Basu
R
, Caprio
S
, Garvey
WT
, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD)
. Endocr Pract
. 2022
;28
(5
):528
–62
. 2.
Attia
SL
, Softic
S
, Mouzaki
M
. Evolving role for pharmacotherapy in NAFLD/NASH
. Clin Transl Sci
. 2021
;14
(1
):11
–9
. 3.
Powell
EE
, Wong
VW
, Rinella
M
. Non-alcoholic fatty liver disease
. Lancet
. 2021
;397
(10290
):2212
–24
. 4.
Sheka
AC
, Adeyi
O
, Thompson
J
, Hameed
B
, Crawford
PA
, Ikramuddin
S
. Nonalcoholic steatohepatitis: a review
. JAMA
. 2020
;323
(12
):1175
–83
. 5.
Lebeaupin
C
, Vallée
D
, Hazari
Y
, Hetz
C
, Chevet
E
, Bailly-Maitre
B
. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease
. J Hepatol
. 2018
;69
(4
):927
–47
. 6.
Joly
AL
, Deepti
A
, Seignez
A
, Goloudina
A
, Hebrard
S
, Schmitt
E
, et al. The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development
. Oncogene
. 2016
;35
(22
):2948
. 7.
Ozcan
U
, Cao
Q
, Yilmaz
E
, Lee
AH
, Iwakoshi
NN
, Ozdelen
E
, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes
. Science
. 2004
;306
(5695
):457
–61
. 8.
Wang
Q
, Zhou
H
, Bu
Q
, Wei
S
, Li
L
, Zhou
J
, et al. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis
. J Hepatol
. 2022
;77
(2
):312
–25
. 9.
Olivares
S
, Henkel
AS
. Hepatic Xbp1 gene deletion promotes endoplasmic reticulum stress-induced liver injury and apoptosis
. J Biol Chem
. 2015
;290
(50
):30142
–51
. 10.
Lerner
AG
, Upton
JP
, Praveen
PV
, Ghosh
R
, Nakagawa
Y
, Igbaria
A
, et al. IRE1α induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress
. Cell Metab
. 2012
;16
(2
):250
–64
. 11.
Puri
P
, Mirshahi
F
, Cheung
O
, Natarajan
R
, Maher
JW
, Kellum
JM
, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease
. Gastroenterology
. 2008
;134
(2
):568
–76
. 12.
Dasgupta
D
, Nakao
Y
, Mauer
AS
, Thompson
JM
, Sehrawat
TS
, Liao
CY
, et al. IRE1A stimulates hepatocyte-derived extracellular vesicles that promote inflammation in mice with steatohepatitis
. Gastroenterology
. 2020
;159
(4
):1487
–503.e17
. 13.
Cha
SH
, Hwang
Y
, Heo
SJ
, Jun
HS
. Diphlorethohydroxycarmalol attenuates palmitate-induced hepatic lipogenesis and inflammation
. Mar Drugs
. 2020
;18
(9
):475
. 14.
Rakipovski
G
, Rolin
B
, Nohr
J
, Klewe
I
, Frederiksen
KS
, Augustin
R
, et al. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-/-) and LDLr(-/-) mice by a mechanism that includes inflammatory pathways
. JACC Basic Transl Sci
. 2018
;3
(6
):844
–57
. 15.
Newsome
PN
, Buchholtz
K
, Cusi
K
, Linder
M
, Okanoue
T
, Ratziu
V
, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
. N Engl J Med
. 2021
;384
(12
):1113
–24
. 16.
Newsome
P
, Francque
S
, Harrison
S
, Ratziu
V
, Van Gaal
L
, Calanna
S
, et al. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
. Aliment Pharmacol Ther
. 2019
;50
(2
):193
–203
. 17.
O'Neil
PM
, Birkenfeld
AL
, McGowan
B
, Mosenzon
O
, Pedersen
SD
, Wharton
S
, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
. Lancet
. 2018
;392
(10148
):637
–49
. 18.
Niu
S
, Chen
S
, Chen
X
, Ren
Q
, Yue
L
, Pan
X
, et al. Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
. Front Endocrinol
. 2022
;13
:1046130
. 19.
Li
R
, Ye
Z
, She
D
, Fang
P
, Zong
G
, Hu
K
, et al. Semaglutide may alleviate hepatic steatosis in T2DM combined with NFALD mice via miR-5120/ABHD6
. Drug Des Devel Ther
. 2022
;16
:3557
–72
. 20.
Pyke
C
, Heller
RS
, Kirk
RK
, Ørskov
C
, Reedtz-Runge
S
, Kaastrup
P
, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody
. Endocrinology
. 2014
;155
(4
):1280
–90
. 21.
McLean
BA
, Wong
CK
, Kaur
KD
, Seeley
RJ
, Drucker
DJ
. Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide
. JCI Insight
. 2021
;6
(22
):e153732
. 22.
Somm
E
, Montandon
SA
, Loizides-Mangold
U
, Gaia
N
, Lazarevic
V
, De Vito
C
, et al. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet
. Transl Res
. 2021
;227
:75
–88
. 23.
Yoshida
H
, Matsui
T
, Yamamoto
A
, Okada
T
, Mori
K
. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor
. Cell
. 2001
;107
(7
):881
–91
. 24.
Ri
M
, Tashiro
E
, Oikawa
D
, Shinjo
S
, Tokuda
M
, Yokouchi
Y
, et al. Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing
. Blood Cancer J
. 2012
;2
(7
):e79
. 25.
Loomba
R
, Friedman
SL
, Shulman
GI
. Mechanisms and disease consequences of nonalcoholic fatty liver disease
. Cell
. 2021
;184
(10
):2537
–64
. 26.
Petersen
MC
, Shulman
GI
. Mechanisms of insulin action and insulin resistance
. Physiol Rev
. 2018
;98
(4
):2133
–223
. 27.
Arab
JP
, Karpen
SJ
, Dawson
PA
, Arrese
M
, Trauner
M
. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives
. Hepatology
. 2017
;65
(1
):350
–62
. 28.
Perepelyuk
M
, Terajima
M
, Wang
A
, Georges
P
, Janmey
P
, Yamauchi
M
, et al. Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury
. Am J Physiol Gastrointest Liver Physiol
. 2013
;304
(6
):G605
–14
. 29.
Friedman
SL
, Neuschwander-Tetri
BA
, Rinella
M
, Sanyal
AJ
. Mechanisms of NAFLD development and therapeutic strategies
. Nat Med
. 2018
;24
(7
):908
–22
. 30.
Barreby
E
, Chen
P
, Aouadi
M
. Macrophage functional diversity in NAFLD — more than inflammation
. Nat Rev Endocrinol
. 2022
;18
(8
):461
–72
. 31.
Gao
R
, Li
Y
, Xu
Z
, Zhang
F
, Xu
J
, Hu
Y
, et al. Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease
. Hepatology
. 2023
;78
(6
):1800
–15
. 32.
Deng
GH
, Wu
CF
, Li
YJ
, Shi
H
, Zhong
WC
, Hong
MK
, et al. Caveolin-1 is critical for hepatic iron storage capacity in the development of nonalcoholic fatty liver disease
. Mil Med Res
. 2023
;10
(1
):53
. 33.
Remmerie
A
, Martens
L
, Thoné
T
, Castoldi
A
, Seurinck
R
, Pavie
B
, et al. Osteopontin expression identifies a subset of recruited macrophages distinct from kupffer cells in the fatty liver
. Immunity
. 2020
;53
(3
):641
–57.e14
. 34.
Tran
S
, Baba
I
, Poupel
L
, Dussaud
S
, Moreau
M
, Gélineau
A
, et al. Impaired kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis
. Immunity
. 2020
;53
(3
):627
–40.e5
. 35.
Seidman
JS
, Troutman
TD
, Sakai
M
, Gola
A
, Spann
NJ
, Bennett
H
, et al. Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis
. Immunity
. 2020
;52
(6
):1057
–74.e7
. 36.
Chou
JW
, Bushel
PR
. Discernment of possible mechanisms of hepatotoxicity via biological processes over-represented by co-expressed genes
. BMC Genomics
. 2009
;10
:272
. 37.
Margariti
A
, Li
H
, Chen
T
, Martin
D
, Vizcay-Barrena
G
, Alam
S
, et al. XBP1 mRNA splicing triggers an autophagic response in endothelial cells through BECLIN-1 transcriptional activation*
. J Biol Chem
. 2013
;288
(2
):859
–72
. 38.
Zhang
Z
, Qian
Q
, Li
M
, Shao
F
, Ding
WX
, Lira
VA
, et al. The unfolded protein response regulates hepatic autophagy by sXBP1-mediated activation of TFEB
. Autophagy
. 2021
;17
(8
):1841
–55
. 39.
Zhang
Y
, Jiao
Y
, Tao
Y
, Li
Z
, Yu
H
, Han
S
, et al. Monobutyl phthalate can induce autophagy and metabolic disorders by activating the ire1a-xbp1 pathway in zebrafish liver
. J Hazard Mater
. 2021
;412
:125243
. 40.
Christou
GA
, Katsiki
N
, Blundell
J
, Fruhbeck
G
, Kiortsis
DN
. Semaglutide as a promising antiobesity drug
. Obes Rev
. 2019
;20
(6
):805
–15
. 41.
Pontes-da-Silva
RM
, de Souza Marinho
T
, de Macedo Cardoso
LE
, Mandarim-de-Lacerda
CA
, Aguila
MB
. Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist
. Int J Obes
. 2022
;46
(1
):21
–9
. 42.
Ghorpade
DS
, Ozcan
L
, Zheng
Z
, Nicoloro
SM
, Shen
Y
, Chen
E
, et al. Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance
. Nature
. 2018
;555
(7698
):673
–7
. 43.
Martinon
F
, Chen
X
, Lee
AH
, Glimcher
LH
. TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages
. Nat Immunol
. 2010
;11
(5
):411
–8
. 44.
Guillory
B
, Jawanmardi
N
, Iakova
P
, Anderson
B
, Zang
P
, Timchenko
NA
, et al. Ghrelin deletion protects against age-associated hepatic steatosis by downregulating the C/EBPα-p300/DGAT1 pathway
. Aging Cell
. 2018
;17
(1
):e12688
. 45.
Akiyama
M
, Liew
CW
, Lu
S
, Hu
J
, Martinez
R
, Hambro
B
, et al. X-box binding protein 1 is essential for insulin regulation of pancreatic α-cell function
. Diabetes
. 2013
;62
(7
):2439
–49
. 46.
Vandewynckel
YP
, Laukens
D
, Bogaerts
E
, Paridaens
A
, Van den Bussche
A
, Verhelst
X
, et al. Modulation of the unfolded protein response impedes tumor cell adaptation to proteotoxic stress: a PERK for hepatocellular carcinoma therapy
. Hepatol Int
. 2015
;9
(1
):93
–104
. 47.
Shuda
M
, Kondoh
N
, Imazeki
N
, Tanaka
K
, Okada
T
, Mori
K
, et al. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis
. J Hepatol
. 2003
;38
(5
):605
–14
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
